Brief: Orexo Announces Positive Data For Powder-Based Intranasal Vaccine
10/04/2025 09:33
April 10 (Reuters) - Orexo AB ORX.ST: OREXO ANNOUNCES POSITIVE DATA FOR POWDER-BASED INTRANASAL VACCINE FORMULATED WITH THE AMORPHOX TECHNOLOGY Source text: ID:nPn534qZga Further company coverage: ORX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens